About ReShape Lifesciences, Inc. - Common Stock (RSLS)
Reshape Lifesciences Inc is a biotechnology company focused on developing innovative medical technologies and solutions for weight management and obesity-related health issues. The company's primary aim is to enhance patient outcomes through its proprietary products, which include minimally invasive procedures designed to aid in weight loss and promote healthier lifestyles. By leveraging advanced engineering and clinical expertise, Reshape Lifesciences seeks to address the growing global health crisis associated with obesity and its complications, ultimately striving to empower individuals to take control of their health through effective interventions. Read More
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
IRVINE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (“ReShape” or the “Company”) (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 1,054,604 shares of common stock at a public offering price of $2.50 per share. Gross proceeds from the offering are expected to be approximately $2.6 million before deducting placement agent fees and other offering expenses. The offering is expected to close on or about June 9, 2025, subject to the satisfaction of customary closing conditions.
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
IRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Quality Management System (QMS) and entire commercial portfolio of medical devices sold in Europe and in the United Kingdom (UK) have been certified under the European Union (EU) Medical Device Regulation (MDR) (EU) 2017/745 and UK Conformity Assessment (UKCA), respectively.
